Meta‐Analysis of Natural Therapies for Hyperlipidemia: Plant Sterols and Stanols versus Policosanol
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Study Objective. To compare the efficacy and safety of plant sterols and stanols as well as policosanol in the treatment of coronary heart disease, as measured by a reduction in low‐density lipoprotein cholesterol (LDL) levels. Design. Systematic review and meta‐analysis of randomized controlled trials. Patients. A total of 4596 patients from 52 eligible studies. Measurements and Main Results. We searched MEDLINE, EMBASE, the Web of Science, and the Cochrane Library from January 1967–June 2003 to identify pertinent studies. Reduction of LDL levels was the primary end point; effects on other lipid parameters and withdrawal of study patients due to adverse effects were the secondary end points. Weighted estimates of percent change in LDL were −11.0% for plant sterol and stanol esters 3.4 g/day (range 2–9 g/day [893 patients]) versus −2.3% for placebo (769 patients) in 23 eligible studies, compared with −23.7% for policosanol 12 mg/day (range 5–40 mg/day [1528 patients]) versus −0.11% for placebo (1406 patients) in 29 eligible studies. Cumulative p values were significantly different from placebo for both (p<0.0001). The net LDL reduction in the treatment groups minus that in the placebo groups was greater with policosanol than plant sterols and stanols (−24% versus −10%, p<0.0001). Policosanol also affected total cholesterol, high‐density lipoprotein cholesterol (HDL), and triglyceride levels more favorably than plant sterols and stanols. Policosanol caused a clinically significant decrease in the LDL:HDL ratio. Pooled withdrawal rate due to adverse effects and combined relative risk for patients who withdrew were 0% and 0.84, respectively (95% confidence interval [CI] 0.36–1.95, p=0.69), for plant sterols and stanols across 20 studies versus 0.86% and 0.31, respectively (95% CI 0.20–0.48, p<0.0001), for policosanol across 28 studies. Conclusion. Plant sterols and stanols and policosanol are well tolerated and safe; however, policosanol is more effective than plant sterols and stanols for LDL level reduction and more favorably alters the lipid profile, approaching antilipemic drug efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Miettinen, T. A., Puska, P., Gylling, H., Vanhanen, H., & Vartiainen, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332002 · Cited by 739
Plant sterol and stanol margarines and health
Law, M. (2000) · BMJ · doi:10.1136/bmj.320.7238.861 · Cited by 729
Jenkins, D. J. A. (2003) · JAMA · doi:10.1001/jama.290.4.502 · Cited by 620
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
MAS, R., CASTANO, G., ILLNAIT, J., FERNANDEZ, L., FERNANDEZ, J., ALEMAN, C., PONTIGAS, V, & LESCAY, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70139-6 · Cited by 130
Cited by
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,555
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.020 · Cited by 757
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update
Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., Ganiats, T. G., Gomes, A. S., Gornik, H. L., Gracia, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181546 · Cited by 579
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O., Djuric, D. M., Ezhov, M., Fras, Z., Katsiki, N., Langlois, M., Latkovskis, G., et al. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux047 · Cited by 295
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O., Djuric, D. M., Ezhov, M., Fras, Z., Katsiki, N., Langlois, M., Latkovskis, G., et al. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.69326 · Cited by 281
“The interest in policosanols has increased based on early Cuban studies, indicating the lipid-lowering and antiplatelet effects of this nutraceutical [124].”
BackgroundWhich interventions offer best value for money in primary prevention of cardiovascular disease
Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041842 · Cited by 97
“4 g of plant sterols are required each day to achieve a beneficial effect [43].”
BackgroundPirro, M., Vetrani, C., Bianchi, C., Mannarino, M. R., Bernini, F., & Rivellese, A. A. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.122 · Cited by 99
Ogier, N., Amiot, M.-J., Georgé, S., Maillot, M., Mallmann, C., Maraninchi, M., Morange, S., Lescuyer, J.-F., Peltier, S. L., & Cardinault, N. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0357-x · Cited by 49
Reiner, ?., Tedeschi-Reiner, E., & Romi??, ?. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525110-00003 · Cited by 47
Metadata
- Authors
- Chen, J. T., Wesley, R., Shamburek, R. D., Pucino, F., & Csako, G.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 25
- Issue
- 2
- Pages
- 171-183
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2043042777
- Cited by
- 129
- References
- 6
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.